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Abstract
Objective The purpose of this study was to give an overview
of the measures used to prevent chronic radiation proctitis
(CRP) and to provide an algorithm for the treatment of CRP.
Methods Medical literature databases including PubMed and
Medline were screened and critically analyzed for relevance in
the scope of our purpose.
Results CRP is a relatively frequent late side effect (5–20%)
and mainly dependent on the dose and volume of irradiated
rectum. Radiation treatment (RT) techniques to prevent
CRP are constantly improving thanks to image-guided
RT and intensity-modulated RT. Also, newer techniques
like protons and new devices such as rectum spacers and
balloons have been developed to spare rectal structures.
Biopsies do not contribute to diagnosing CRP and should
be avoided because of the risk of severe rectal wall dam-
age, such as necrosis and fistulas. There is no consensus
on the optimal treatment of CRP. A variety of possibilities is
available and includes topical and oral agents, hyperbaric oxy-
gen therapy, and endoscopic interventions.
Conclusions CRP has a natural history of improving over time,
even without treatment. This is important to take into account
when considering these treatments: first be conservative (topical
and oral agents) and be aware that invasive treatments can be
very toxic.
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Introduction
Radiation injury to the rectum represents a feared complication
of radiotherapy (RT) in urological, gynecological, and gastroin-
testinal malignancies (prostate, urinary bladder, cervix, uterus,
and anus). Chronic radiation proctitis (CRP) is a relatively fre-
quent late (after 3–6 months) side effect that affects 5–20 % of
cancer patients [1–3]. The probability of developing the injury is
related to the volume of rectum irradiated, total RT dose, RT
technique, and dose per fraction [4]. Also, individual patient
factors can influence the susceptibility to CRP: comorbidity of
vascular disease, diabetes, connective tissue disease or inflam-
matory bowel disease, specific conditions such as smoking, and
concomitant chemotherapy [5, 6]. Published nomograms based
on patient risk factors (use of anti-coagulants, hormonal therapy,
or anti-hypertensives; presence of diabetes or hemorrhoids, and
a history of pre-RTabdominal surgery) have been predictive for
CRP in prostate cancer [7, 8].
Until now, no optimal management has been defined for
CRP. A variety of therapeutic modalities is available ranging
from oral agents to endoscopic interventions. The aim of this
article is to summarize the measures being developed for the
prevention of CRP and to present a practical algorithm for the
treatment of CRP based on a review of the literature.
Symptoms
RT can cause both early (acute) and late (chronic) side effects
[9]. Acute side effects by definition occur up to 3 months after
RT and are usually self-limiting. Chronic side effects occur 3–
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6 months after RT or even years later. The side effects of RT
are scored in five groups (see Table 1) according to the Na-
tional Cancer Institute Common Terminology Criteria for Ad-
verse Events 4.0 (CTCAE) [10]. Acute side effects include
diarrhea, mucus discharge, urgency, tenesmus, and uncom-
monly bleeding [5]. Similar symptoms are seen in patients
with chronic CRP, but bleeding is the most common symp-
tom, with potential iron-deficiency anemia that requires blood
transfusions. In addition, patients may have symptoms of
obstructed defecation due to strictures with symptoms of con-
stipation, rectal pain, urgency, and, rarely, fecal incontinence
due to overflow [5]. In a series of studies, Andreyev et al.
identified 23 different symptoms that develop after pelvic
RT [11–13].
Pathogenesis
CRP results from progressive epithelial atrophy and fibrosis
associated with obliterative endarteritis, chronic mucosal is-
chemia, submucosal fibrosis, and new vessel formation,
which have been shown to lead to clinical symptoms [14].
This is not further discussed here because they go beyond
the scope of this article and can be found elsewhere [14, 15].
Diagnosis
CRP should be suspected in any patient who has had
pelvic RT and presents with the symptoms mentioned
above, even if the radiotherapy took place years ago. Di-
agnosis by endoscopy is important to exclude other causes
of proctitis (infectious colitis, inflammatory bowel dis-
ease, diversion colitis, ischemic colitis, diverticular coli-
tis) and a second malignancy [15].
Endoscopy is also important to determine the extent and
severity of CRP. There are three main forms of endoscopic
findings in CRP: inflammation predominant form (I-CRP)
(edema, mucosal pallor, and ulcer), bleeding predominant
form (B-CRP) (friability, spontaneous hemorrhage, and telan-
giectasia), and a mixed form (with features from both I-CRP
and B-CRP) (Fig. 1a–d) [15–17]. The endoscopic classifica-
tion of CRP is usually analyzed by the Vienna Rectoscopy
Score (VRS) to describe rectal mucosa [18]. The VRS divides
the inner rectal mucosa into 12 mucosal areas. Furthermore,
each area is scored on the presence and grading of telangiec-
tasia (Grade 0–3), congested mucosa (Grade 0–3), ulceration
(Grade 0–4), stricture (Grade 0–4), and necrosis (Grade 0–1).
However, other scoring systems also exist [19].
Rectal wall biopsies should be avoided as they may initiate
chronic, poorly healing wounds. A number of studies have
also described fistula formation over the prostate following
rectal biopsies [20–22]. Therefore, a biopsy is only justified
if a malignancy is suspected or in case of important therapeu-
tic consequences. In these cases, biopsies should be taken
from the posterior and lateral rectal walls to avoid the anterior
irradiated high-dose areas [20]. In conclusion, biopsies do not
really contribute to the diagnosis of CRP and should be
avoided.
Prevention
Excluding the rectum from the irradiation fields to prevent CRP
has a high priority in RT. Optimizing the RT planning by using
planning constraints reduces the irradiated rectal volume and
consequently decreases the risk of rectal toxicity [23].
There is increasing evidence supporting the role of genetic
variants in the development of RT-induced toxicity [24]. Re-
cently, the first replicated genetic associations for adverse re-
actions to RT were reported [25]. Active research to identify
high-risk patients is based on genetic biomarkers [26] that
could allow radiotherapists to select patients for which extra
care should be taken to decrease the dose to the rectum.
Different RT techniques
The use of modern RT techniques (intensity-modulated
RT) and the use of implanted fiducial markers into the
prostate (image-guided RT) minimize the dose of radia-
tion to the rectum while maximizing the dose to the pros-
tate [27–29].
Newer RT techniques which utilize heavy particles such as
protons and carbon ions are currently being developed and
tested to improve outcomes with reduced toxicity [30, 31].
Carbon ions seem to be better protective than protons which
can be explained by the steeper dose gradients achieved by
heavier particles [32]. Although these methods have the po-
tential to deliver optimal doses of radiation to the tumor with
only minimal exposure to the surrounding normal tissues, the
long-term outcomes are not yet clear.
Table 1 Radiation proctitis according to the ‘common toxicity criteria’,
version 4
Grade CRP Symptoms
1 Rectal discomfort; intervention not indicated
2 Symptoms (rectal discomfort, passing blood
or mucus); medical intervention indicated;
limiting instrumental ADL
3 Severe symptoms; fecal urgency or stool
incontinence; limiting self-care ADL
4 Life-threatening consequences; urgent
intervention indicated
5 Death
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Medication
The use of medical therapy (amifostine, sucralfate, 5-
aminosalicylic acid, or sulphasalazine) to prevent the devel-
opment of CRP has only a minimal effect and is not widely
used [33–36]. Placebo-controlled phase III trials have shown
no benefit from either topical or oral sucralfate [37]. However,
higher doses of amifostine are described as tolerable and as
having a better protective effect against the early and late
short-term effects of RT [38].
Newer insights have revealed that synbiotics and
microbiotics can be used to manipulate the intestinal flora to
prevent and treat CRP [39, 40]. Further research is needed to
confirm those preliminary data.
Rectum spacer
Devices have been developed to spare rectal structures
[41]. These can be divided into endorectal balloons and
relatively novel rectum spacers. Endorectal balloons are
inserted into the rectum for each daily treatment fraction
to increase the distance from the dorsal rectal wall to the
prostate. Although the anterior anorectal wall is pushed
towards the prostate, the overall effect proved to be ben-
eficial in 3D-conformal RT and intensity-modulated RT
[42]. Rectum spacers are implanted as a tissue filler into
the anterior perirectal fat to separate the rectum from the
prostate (Fig. 2). Increasing the prostate-rectum distance dis-
places the rectal wall away from the prostate and out of the
regions of high-dose RT. The overall effect is a reduction in
the maximum dose to the rectum and the total volume of
irradiated rectum. The implantation of such rectum spacers
is typically performed transperineally under real-time
transrectal ultrasound guidance. The insertion procedure can
be performed under local (with or without sedation), spinal, or
general anesthesia [43]. The implanted rectum spacer remains
in place over the course of the RT treatment, and the spacer
biodegrades naturally within 6 months after implantation [44].
Different types of rectum spacers have been developed: an
absorbable hydrogel, a hyaluronic acid, a collagen, and a
saline-filled balloon [44–46]. Several studies are available
on the dosimetry, acute outcome, and cost-effectiveness of a
rectum spacer; however, no long-term results are available yet
[47–56].
Treatment
A wide variety of interventions have been tried for treating
CRP. There have been no large controlled randomized trials
to evaluate the treatment of CRP. Also, several studies have
resulted in ambiguous outcome measurements, showing no
structured outcome measurement to describe and compare
the findings from different trials. Some studies used the
Fig. 1 Endoscopic features
illustrating the different grades of
CRP at the anterior rectum wall. a




bleeding form of CRP, c
illustrates necrosis with multiple
confluent telangiectatic lesions,
and d shows an ulcer
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VRS scoring system to evaluate treatments; others used dif-
ferent clinical outcomes. Thus, experience is derived mostly
from small clinical trials, expert opinions, and case reports
[57, 58]. Interventions can broadly be categorized into
medical therapies, endoscopic therapies, and surgical in-
terventions. Medical therapy is the main stay of treatment
for I-CRP. Endoscopy is the main treatment modality for
B-CRP if the bleeding is affecting quality of life [15]. It is
very important to realize, when considering invasive treat-
ments, that CRP can improve over time without any ac-
tive treatment [59].
In patients with CRP, treatment should be based upon
the pattern and severity of symptoms and experience at
the treatment center. A treatment algorithm is presented
in Fig. 3 for this purpose. For patients with minor
symptoms that do not affect their quality of life, no
treatment may be indicated because CRP has a natural
history of improving over time without treatment. For
patients with I-CRP, Andreyev et al. published a treat-
ment guide that recommends loperamide, fibers, stool-
bulking agents, and corticosteroids [13]. Patients with
B-CRP and physical complaints of anemia (dyspnoe
d’effort, palpitations, fatigue) should be monitored for
anemia and where appropriate given iron supplements
or blood transfusion. If necessary, endoscopic treatment
is also indicated [60]. B-CRP is the most common form,
and therefore, most studies have concentrated and pub-
lished on B-CRP.
Medical treatment of B-CRP
Medical treatments with level I evidence of benefits in small
randomized trials are listed here: sucralfate enema [61, 62],
metronidazole [63], vitamin A [64], and hyperbaric oxygen
therapy (HOT) [65].
Sucralfate enema
Sucralfate is an aluminum salt that adheres to mucosal cells
and stimulates prostaglandin production, producing
cytoprotective effects. It has been used in the treatment of
peptic ulcers [66].
In a prospective randomized trial, Kochhar et al. reported
37 patients with RT-induced CRP who were assigned to a 4-
week course of sulfasalazine (3 g/day) plus prednisolone en-
emas (20 mg 2×/day) or sucralfate enemas (2 g 2×/day) [61].
Kochhar et al. subsequently reported in a prospective
study on 26 patients with moderate to severe CRP who
were treated with 20-ml sucralfate enemas twice daily
until bleeding stopped or failure of therapy was acknowl-
edged. Response to the therapy was considered good
when the severity of bleeding improved by two grades.
This was observed in 77 % of patients [62]. Kochhar et al.
concluded that sucralfate enemas give a better clinical
response and are better tolerated.
Although placebo-controlled randomized trials are needed
to fully assess efficacy, sucralfate is recommended as the pre-
ferred mode of short-term treatment.
Metronidazole
Anti-microbial agents could be effective in CRP because of
their immune-modulatory effects [67] and selective toxicity to
microorganisms that contribute to the pathogenesis of CRP
[68].
Cavcic et al. reported on 60 patients with CRP who re-
ceived mesalazine (1 g 3×/day) and a betamethasone enema
(1/day during 4 weeks) with or without oral metronidazole
(400 mg 3×/day) [63]. The addition of metronidazole was
associated with a reduction in rectal bleeding, diarrhea, and
ulcers at 4 weeks, 3 months, and 12 months. This trial
Fig. 2 Axial T2-weighted
magnetic resonance images of a
patient with a hydrogel spacer
before injection (a) and after
injection (b)
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suggested that metronidazole can improve symptoms and mu-
cosal healing in combination with anti-inflammatory
treatments.
Vitamin A/E/C
Antioxidants were suggested to have cytoprotective effects by
reducing cellular oxidative stress following radiation injury to
intestinal tissue [69].
Ehrenpreis et al. reported on a prospective double-blind
trial including 19 patients with CRP 6 months after RT who
were randomized to receive oral vitamin A (10,000 IU 2×/day,
during 90 days) or a placebo. Vitamin A significantly reduced
rectal symptoms of CRP [64].
Kennedy et al. reported on 20 patients treated for symp-
tomatic CRP with oral vitamin E (400 IU 3×/day) and vitamin
C (500 mg 3×/day). Bleeding resolved in 4 of 11 patients, and
diarrhea resolved in 50 % of patients [70].
Hyperbaric oxygen therapy
HOT involves patients breathing pure oxygen in a pres-
surized room or tube. In a HOT chamber, the air pressure
is increased to three times higher than normal air pres-
sure [71]. Under these conditions, the lungs can gather
more oxygen than at normal air pressure. This higher
oxygenated blood may be beneficial because it inhibits
bacterial growth and stimulates the release of growth
factors and stem cells, which promotes wound healing.
It may even reverse progressive changes caused by RT
and may improve other symptoms such as urinary prob-
lems [72, 73].
Clarke [65] performed a controlled randomized trial with
groups that were randomized to HOTat 2.0 atm absolute or air
at 1.1 atm absolute. HOT significantly improved the healing
responses in patients with refractory CRP, generating an ab-
solute risk reduction of 32 % (number needed to treat, 3) [65].
Clinical suspicion CRP:
Symptoms start 3 months to years after RT 
Examinations: 
Flexible endoscopy to determine the cause.
Laboratory: hemoglobin-iron state
Treatment:
Optimize bowel function and stool consistency 
to reduce the amount of bleeding.
Start eventually antioxidantia (Vit. A,E,C) / 
Antibiotics (Metronidazole)
If bleeding is not affecting quality of life 
- Reassure
- Do nothing further.
If bleeding is affecting quality of life,
- stop/reduce anticoagulants if possible 
- start sucralfate enemas.
Discuss definitive treatment to ablate 
the telangiectasia with the patient
Be aware of iatrogenic problems!
If accessible
Hyperbaric oxygen therapy 
Formalin therapy Argon plasma coagulation 
If fistulas/strictures not healing
Surgery 
Inflammation - predominant form of CRPBleeding - predominant form of CRP
Treatment:
Loperamide, fibers, stool bulking 
agents, corticosteroids
Fig. 3 Algorithm for treatment of
CRP
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A Cochrane review revealed a significantly increased
chance of improvement or cure following HOT for CRP
(RR 1.72; 95 % CI 1.0 to 2.9, p 0.04) [74].
Unfortunately, hyperbaric oxygen facilities are not always
available, so patients may need to travel long distances to their
nearest unit, and treatments are time-consuming (60–120 min
for 30–70 sessions) and expensive [75].
Endoscopic treatment
Avariety of endoscopic therapies is available for rectal bleed-
ing caused by CRP including argon plasma coagulation
(APC), topical formalin, laser, heater, and bipolar probes.
There is no level I evidence of benefit in randomized trials.
The goal of endoscopic treatments of CRP is to control bleed-
ing. Endoscopic treatments may require multiple procedures
and can have very significant adverse effects [60]. Due to a
known high-potential risk of fistulas and ulcerations in the
first 2 years after RT, we advise that all endoscopic treatments
should be performed by an experienced gastroenterologist
with particular awareness of post-RT rectal injury in close
collaboration with a pelvic radiation oncologist [76].
Argon plasma coagulation
APC is a form of electrocautery, in which a monopolar dia-
thermy is transmitted to the target tissue through an ionized
gas in a non-contact fashion (0.8–3.0 mm from the target)
[77]. APC is considered by many gastroenterologists as the
treatment of choice for CRP [78–81]. However, it should be
used with caution in this patient group. Complications such as
bowel explosions following the use of APC in inadequately
prepared bowels have been described but are preventable [82].
Other severe side effects, such as the occurrence of deep ul-
ceration [83, 84], fistulation [85], stricture formation [86–88],
bleeding [83, 84, 89], perforation [83], and severe and some-
times chronic pain [80, 89, 90], reflect the risk of any therapy
in chronically ischemic tissues. Rectal ulcers after APC when
used for CRP are observed in approximately 26 % of patients,
in one series, even up to 52 % [91–93]. Together with
restricting argon flow rates and wattage, a very precise and
brief application of the argon catheter could potentially reduce
complication rates [94]. In specialist centers, serious compli-
cations of previous APC treatment in this patient group con-
tinue to be seen regularly [60].
Swan et al. presented a complete resolution of bleeding in
72 % of 50 patients who had bleeding CRP [79]. Thirty-four
percent of the patients experienced short-term, self-limiting
complications; 2 % experienced a long-term complication.
The setting was a tertiary referral hospital, where only dedi-
cated and experienced gastroenterologists were involved in
post-RT rectal injury.
Topical formalin
Formalin seals fragile neovasculature in radiation-damaged
tissues to prevent further bleeding through chemical cauteri-
zation [95, 96]. This treatment is simple to perform, but a
severe disadvantage is a chemical burn to the skin if there is
spillage [60].
There are several small retrospective studies on the use of
formalin. These studies used a variety of formalin application
techniques, from irrigation to direct application, and formalin
concentrations, from 3.6 to 10 % [97]. The short-term success
rate of this technique ranged from 60 to 100 % [98–109].
However, the procedure is not risk free and may induce major
complications such as acute colitis [110].
Yeoh et al. showed that APC and topical formalin had
comparable efficacy in the durable control of rectal bleeding
associated with CRP but had no beneficial effect on anorectal
dysfunction [111]. However, more authors reported that APC
may be more effective in treating CRP as compared with for-
malin therapy [58, 89, 112].
Laser
The argon and neodymium/yttrium aluminum garnet
(Nd:YAG) laser has been used to coagulate bleeding vessels
throughout the gastrointestinal tract [113]. A study that includ-
ed 65 patients treated with an Nd:YAG laser found an im-
provement in symptoms in 78 % of patients (range, 58 to
87 %) [114]. However, the laser is expensive and not widely
available.
Assessing the effectiveness of these interventions is com-
plicated by the small number of patients included in many
trials, the lack of a control arm, and the fact that the natural
history of CRP is to improve over time without treatment.
Surgery
Surgery is considered as a last resort for patients with CRP and
should be reserved for those who are found to have a stricture,
permanent bleeding, perforation, or a fistula that is not respon-
sive to the medical and endoscopic approaches [15, 115]. Sur-
gical treatment options include excision, urinary and fecal
diversion (diverting stoma), and reconstruction of a coloanal
J reservoir [116]. Severe postoperative complications can oc-
cur such as sepsis, wound dehiscence, bowel obstruction, and
de novo rectal fistula [76]. Yegappan et al. reported a 3 %
postoperative mortality rate [117].
Fischer et al. concluded that 51% of their participants had a
fair outcome, 34 % had slight or moderate symptoms, and
14 % had disabling symptoms [118]. Lane et al. revealed that
good outcomes can be expected in properly selected patients
[119]. Turina et al. determined that the best results were found
in patients presenting with colorectal anastomotic and primary
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bowel strictures as their main complication, while most pa-
tients with severe CRP and very distal strictures required per-
manent diversion [120].
Conclusion
CRP is a commonly observed late side effect of pelvic RT and
can occur even years after treatment. First of all, care should
be taken to minimize the risk of CRP by improving RT tech-
niques (IMRT, IGRT) or to implement new devices to spare
the rectum (spacers, balloons). On the basis of the available
knowledge, we constructed a practical management algorithm
(Fig. 3). The literature generally recommends a flexible en-
doscopy to determine the cause. Biopsy, and especially ante-
rior rectal biopsy, within the first years of RT should be
avoided, because this augments the risk of a fistula and is
not likely to provide any relevant information.
There are three main forms of CRP: I-CRP, B-CRP, and a
mixed form. I-CRP responds well to loperamide, fibers, stool-
bulking agents, and corticosteroids. B-CRP is often self-
limiting and responds well to conservative management; it is
advisable to stop anti-coagulants, if possible, and start with
antioxidants (vitamin A, E, C) and/or antibiotics (metronida-
zole). If no response is observed, patients should be started on
sucralfate enemas. In severe cases, with persistent bleeding,
chemical (formalin) or thermal (coagulation) treatments are
successful. If HOT is available, it may also be a good option.
Surgery should be considered as the last resort and is only
indicated if fistulas and strictures are not healing. Although
surgery can lead to significant improvements, it also bears an
increased risk of postsurgical complications. Based on the
frequency of CRP, prospective controlled and larger studies
are advised to increase our knowledge about both the preven-
tion and treatment of CRP.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Garg AK, Mai WY, McGary JE, Grant WH 3rd, Butler EB, Teh
BS (2006) Radiation proctopathy in the treatment of prostate can-
cer. Int J Radiat Oncol Biol Phys 66(5):1294–1305. doi:10.1016/j.
ijrobp.2006.07.1386
2. Kuku S, Fragkos C, McCormack M, Forbes A (2013) Radiation-
induced bowel injury: the impact of radiotherapy on survivorship
after treatment for gynaecological cancers. Br J Cancer 109(6):
1504–1512. doi:10.1038/bjc.2013.491
3. Krol R, Smeenk RJ, van Lin EN, Yeoh EE, Hopman WP (2014)
Systematic review: anal and rectal changes after radiotherapy for
prostate cancer. Int J Color Dis 29(3):273–283. doi:10.1007/
s00384-013-1784-8
4. Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP,
Chen RC, O’Leary MP, Kantoff PW, D’Amico AV (2003) Time
course and predictors of symptoms after primary prostate cancer
therapy. J Clin Oncol 21(21):3979–3986. doi:10.1200/JCO.2003.
01.199
5. Shadad AK, Sullivan FJ, Martin JD, Egan LJ (2013)
Gastrointestinal radiation injury: symptoms, risk factors and
mechanisms. World J Gastroenterol 19(2):185–198. doi:10.
3748/wjg.v19.i2.199
6. Theis VS, Sripadam R, Ramani V, Lal S (2010) Chronic radiation
enteritis. Clin Oncol (R Coll Radiol) 22(1):70–83. doi:10.1016/j.
clon.2009.10.003
7. Valdagni R, Rancati T, Fiorino C, Fellin G,Magli A, Baccolini M,
Bianchi C, Cagna E, Greco C, Mauro FA, Monti AF, Munoz F,
Stasi M, Franzone P, Vavassori V (2008) Development of a set of
nomograms to predict acute lower gastrointestinal toxicity for
prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys 71(4):
1065–1073. doi:10.1016/j.ijrobp.2007.11.037
8. Valdagni R, Kattan MW, Rancati T, Yu C, Vavassori V, Fellin G,
Cagna E, Gabriele P, Mauro FA, Baccolini M, Bianchi C,
Menegotti L, Monti AF, Stasi M, Giganti MO, Fiorino C (2012)
Is it time to tailor the prediction of radio-induced toxicity in pros-
tate cancer patients? Building the first set of nomograms for late
rectal syndrome. Int J Radiat Oncol Biol Phys 82(5):1957–1966.
doi:10.1016/j.ijrobp.2011.03.028
9. Dörr W (2015) Radiobiology of tissue reactions. Ann ICRP. doi:
10.1177/0146645314560686
10. National Cancer Institute (2013) Common Terminology Criteria
for Adverse Events (CTCAE) 4.0. http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/ctc.htm. Accessed
18 May 2015
11. Gami B, Harrington K, Blake P, Dearnaley D, Tait D, Davies J,
Norman AR, Andreyev HJ (2003) How patients manage gastro-
intestinal symptoms after pelvic radiotherapy. Aliment Pharmacol
Ther 18(10):987–994. doi:10.1046/j.1365-2036.2003.01760.x
12. Gillespie C, Goode C, Hackett C, Andreyev HJ (2007) The clin-
ical needs of patients with chronic gastrointestinal symptoms after
pelvic radiotherapy. Aliment Pharmacol Ther 26(4):555–563. doi:
10.1111/j.1365-2036.2007.03405
13. Andreyev HJ, Benton BE, Lalji A, Norton C, Mohammed K,
Gage H, Pennert K, Lindsay JO (2013) Algorithm-based manage-
ment of patients with gastrointestinal symptoms in patients after
pelvic radiation treatment (ORBIT): a randomised controlled trial.
Lancet 382(9910):2084–2092. doi:10.1016/s0140-6736(13)
61648-7
14. Leiper K, Morris AI (2007) Treatment of radiation proctitis. Clin
Oncol (R Coll Radiol) 19(9):724–729. doi:10.1016/j.clon.2007.
07.008
15. Wu XR, Liu XL, Katz S, Shen B (2015) Pathogenesis, diagnosis,
and management of ulcerative proctitis, chronic radiation
proctopathy, and diversion proctitis. Inflamm Bowel Dis 21(3):
703–715. doi:10.1097/mib.0000000000000227
16. Moore EM, Magrino TJ, Johnstone PA (2000) Rectal bleeding
after radiation therapy for prostate cancer: endoscopic evaluation.
Radiology 217:215–218. doi:10.1148/radiology.217.1.
r00oc24215
17. Reichelderfer M, Morrissey JF (1980) Colonoscopy in radiation
colitis. Gastrointest Endosc 26:41–43. doi:10.1016/s0016-
5107(80)73265-0
18. Wachter S, Gerstner N, Goldner G, Potzi R, Wambersie A, Potter
R (2000) Endoscopic scoring of late rectal mucosal damage after
Int J Colorectal Dis (2015) 30:1293–1303 1299
conformal radiotherapy for prostatic carcinoma. Radiother Oncol
54(1):11–19. doi:10.1016/s0167-8140(99)00173-5
19. Chi KD, Ehrenpreis ED, Jani AB (2005) Accuracy and reliability
of the endoscopic classification of chronic radiation-induced
proctopathy using a novel grading method. J Clin Gastroenterol
39(1):42–46
20. Chrouser KL, Leibovich BC, Sweat SD, Larson DW, Davis BJ,
Tran NV, Zincke H, Blute ML (2005) Urinary fistulas following
external radiation or permanent brachytherapy for the treatment of
prostate cancer. J Urol 173(6):1953–1957. doi:10.1097/01.ju.
0000158041.77063.ff
21. Theodorescu D, Gillenwater J, Koutrouvelis P (2000)
Prostatourethral-rectal fistula after prostate brachytherapy.
Cancer 89:2085–2091. doi:10.1002/1097-0142(20001115)
89:10<2085::aid-cncr8>3.0.co;2-q
22. Thornhill JA, Long RM, Neary P, O’Connor HJ, Ryan B, Fraser I
(2012) The pitfalls of treating anorectal conditions after radiother-
apy for prostate cancer. Ir Med J 105:91–93
23. Fonteyne V, De Neve W, Villeirs G, De Wagter C, De Meerleer G
(2007) Late radiotherapy-induced lower intestinal toxicity
(RILIT) of intensity-modulated radiotherapy for prostate cancer:
the need for adapting toxicity scales and the appearance of the
sigmoid colon as co-responsible organ for lower intestinal toxicity.
Radiother Oncol 84(2):156–163. doi:10.1016/j.radonc.2007.06.
013
24. West C, Azria D, Chang-Claude J, Davidson S, Lambin P,
Rosenstein B, De Ruysscher D, Talbot C, Thierens H, Valdagni
R, Vega A, Yuille M (2014) The REQUITE project: validating
predictive models and biomarkers of radiotherapy toxicity to re-
duce side-effects and improve quality of life in cancer survivors.
Clin Oncol (R Coll Radiol) 26(12):739–742. doi:10.1016/j.clon.
2014.09.008
25. Fachal L, Gómez-Caamaño A, Barnett GC, Peleteiro P, Carballo
AM, Calvo-Crespo P, Kerns SL, Sánchez-García M, Lobato-
Busto R, Dorling L, Elliott RM, Dearnaley DP, Sydes MR, Hall
E, Burnet NG, Carracedo Á, Rosenstein BS, West CM, Dunning
AM, Vega A (2014) A three-stage genome-wide association study
identifies a susceptibility locus for late radiotherapy toxicity at
2q24.1. Nat Genet 46(8):891–894. doi:10.1038/ng.3020
26. West CM, Barnett GC (2011) Genetics and genomics of radiother-
apy toxicity: towards prediction. Genome Med 3(8):52. doi:10.
1186/gm268
27. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC,
Amols H, Venkatraman ES, Leibel SA (2002) High-dose intensity
modulated radiation therapy for prostate cancer: early toxicity and
biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys
53:1111–1116. doi:10.1016/s0360-3016(02)02857-2
28. DeMeerleer GO, FonteyneVH, Vakaet L, Villeirs GM, Denoyette
L, Verbaeys A, Lummen N, De Neve WJ (2007) Intensity-
modulated radiation therapy for prostate cancer: late morbidity
and results on biochemical control. Radiother Oncol 82:160–
166. doi:10.1016/j.radonc.2006.12.007
29. Wortel RC, Incrocci L, Pos FJ, Lebesque JV, Witte MG, van der
Heide UA, van Herk M, Heemsbergen WD (2015) Acute toxicity
after image-guided intensity modulated radiation therapy com-
pared to 3D conformal radiation therapy in prostate cancer pa-
tients. Int J Radiat Oncol Biol Phys 91(4):737–744. doi:10.1016/
j.ijrobp.2014.12.017
30. Zietman A (2013) Proton beam and prostate cancer: an evolving
debate. Rep Pract Oncol Radiother 18(6):338–342. doi:10.1016/j.
rpor.2013.06.001
31. Shioyama Y, Tsuji H, Suefuji H, SinotoM,Matsunobu A, Toyama
S, Nakamura K, Kudo S (2015) Particle radiotherapy for prostate
cancer. Int J Urol 22(1):33–39. doi:10.1111/iju.12640
32. Georg D, Hopfgartner J, Gòra J, Kuess P, Kragl G, Berger D,
Hegazy N, Goldner G, Georg P (2014) Dosimetric considerations
to determine the optimal technique for localized prostate cancer
among external photon, proton, or carbon-ion therapy and high-
dose-rate or low-dose-rate brachytherapy. Int J Radiat Oncol Biol
Phys 88(3):715–722. doi:10.1016/j.ijrobp.2013.11.241
33. Stellamans K, Lievens Y, Lambin P, Van den Weyngaert D, Van
den Bogaert W, Scalliet P, Hutsebaut L, Haustermans K (2002)
Does sucralfate reduce early side effects of pelvic radiation? A
double-blind randomized trial. Radiother Oncol 65(2):105–108
34. Athanassiou H, Antonadou D, Coliarakis N, Kouveli A,
Synodinou M, Paraskevaidis M, Sarris G, Georgakopoulos GR,
Panousaki K, Karageorgis P, Throuvalas N, Oncology Hellenic
Group (2003) Protective effect of amifostine during fractionated
radiotherapy in patients with pelvic carcinomas: results of a ran-
domized trial. Int J Radiat Oncol Biol Phys 56(4):1154–1160. doi:
10.1016/s0360-3016(03)00187-1
35. Jahraus CD, Bettenhausen D, Malik U, Sellitti M, St Clair WH
(2005) Prevention of acute radiation-induced proctosigmoiditis by
balsalazide: a randomized, double-blind, placebo controlled trial
in prostate cancer patients. Int J Radiat Oncol Biol Phys 63(5):
1483–1487. doi:10.1016/j.ijrobp.2005.04.032
36. Simone NL, Ménard C, Soule BP, Albert PS, Guion P, Smith S,
Godette D, Crouse NS, Sciuto LC, Cooley-Zgela T, Camphausen
K, Coleman CN, Singh AK (2008) Intrarectal amifostine during
external beam radiation therapy for prostate cancer produces sig-
nificant improvements in quality of life measured by EPIC score.
Int J Radiat Oncol Biol Phys 70(1):90–95. doi:10.1016/j.ijrobp.
2007.05.057
37. Kneebone A,Mameghan H, Bolin T, BerryM, Turner S, Kearsley
J, Graham P, Fisher R, Delaney G (2004) Effect of oral sucralfate
on late rectal injury associated with radiotherapy for prostate can-
cer: a double-blind, randomized trial. Int J Radiat Oncol Biol Phys
60(4):1088–1097. doi:10.1016/j.ijrobp.2004.04.033
38. Koukourakis MI, Kyrgias G, Panteliadou M, Papadopoulou A,
Tsiarkatsi M, Papachristou E, Bebeli M (2013) Dose escalation
of amifostine for radioprotection during pelvic accelerated radio-
therapy. Am J Clin Oncol 36(4):338–343. doi:10.1097/coc.
0b013e318248d882
39. Ferreira MR, Muls A, Dearnaley DP, Andreyev HJ (2014)
Microbiota and radiation-induced bowel toxicity: lessons from
inflammatory bowel disease for the radiation oncologist. Lancet
Oncol 15(3):e139–e147. doi:10.1016/s1470-2045(13)70504-7
40. Nascimento M, Aguilar-Nascimento JE, Caporossi C, Castro-
Barcellos HM, Motta RT (2014) Efficacy of synbiotics to reduce
acute radiation proctitis symptoms and improve quality of life: a
randomized, double-blind, placebo-controlled pilot trial. Int J
Radiat Oncol Biol Phys 90(2):289–295. doi:10.1016/j.ijrobp.
2014.05.049
41. Smeenk RJ, van Lin ENJT (2013) Application of anorectal spar-
ing devices in prostate radiotherapy. Radiother Oncol 106(2):155–
156. doi:10.1016/j.radonc.2013.02.004
42. Van Lin EN, Kristinsson J, Philippens ME, de Jong DJ, Van DV,
Kaanders JH, Leer JW, Visser AG (2007) Reduced late rectal
mucosal changes after prostate three-dimensional conformal ra-
diotherapy with endorectal balloon as observed in repeated endos-
copy. Int J Radiat Oncol Biol Phys 67:799–811. doi:10.1016/j.
ijrobp.2006.09.034
43. Hatiboglu G, PinkawaM,Vallee JP, Hadaschik B, HohenfellnerM
(2012) Application technique: placement of a prostate-rectum
spacer in men undergoing prostate radiation therapy. BJU Int
110:e647–e652. doi:10.1111/j.1464-410x.2012.11373.x
44. Mok G, Benz E, Vallee JP, Miralbell R, Zilli T (2014)
Optimization of radiation therapy techniques for prostate cancer
with prostate-rectum spacers: a systematic review. Int J Radiat
Oncol Biol Phys 90(2):278–288. doi:10.1016/j.ijrobp.2014.06.
044
1300 Int J Colorectal Dis (2015) 30:1293–1303
45. PinkawaM (2014) Spacer application for prostate cancer radiation
therapy. Future Oncol 10(5):851–864. doi:10.2217/fon.13.223
46. Schutzer ME, Orio PF, Biagioli MC, Asher DA, Lomas H,
Moghanaki D (2015) A review of rectal toxicity following perma-
nent low dose-rate prostate brachytherapy and the potential value
of biodegradable rectal spacers. Prostate Cancer Prostatic Dis
18(2):96–103. doi:10.1038/pcan.2015.4
47. Prada PJ, Fernández J, Martinez AA, de la Rúa A, Gonzalez JM,
Fernandez JM, Juan G (2007) Transperineal injection of
hyaluronic acid in anterior perirectal fat to decrease rectal toxicity
from radiation delivered with intensity modulated brachytherapy
or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys
69(1):95–102. doi:10.1016/j.ijrobp.2007.02.034
48. Wilder RB, Barme GA, Gilbert RF et al (2010) Cross-linked
hyaluronan gel reduces the acute rectal toxicity of radiotherapy
for prostate cancer. Int J Radiat Oncol Biol Phys 77(3):824–830.
doi:10.1016/j.ijrobp.2009.05.069
49. Susil RC, McNutt TR, DeWeese TL et al (2010) Effects of
prostate-rectum separation on rectal dose from external beam ra-
diotherapy. Int J Radiat Oncol Biol Phys 76:1251–1258. doi:10.
1016/j.ijrobp.2009.07.1679
50. Noyes WR, Hosford CC, Schultz SE (2012) Human collagen
injections to reduce rectal dose during radiotherapy. Int J Radiat
Oncol Biol Phys 82(5):1918–1922. doi:10.1016/j.ijrobp.2011.02.
034
51. Pinkawa M, Corral NE, Caffaro M et al (2011) Application of a
spacer gel to optimize three-dimensional conformal and intensity
modulated radiotherapy for prostate cancer. Radiother Oncol
100(3):436–441. doi:10.1016/j.radonc.2011.09.005
52. Uhl M, van Triest B, Eble MJ, Weber DC, Herfarth K, De Weese
TL (2013) Low rectal toxicity after dose escalated IMRT treatment
of prostate cancer using an absorbable hydrogel for increasing and
maintaining space between the rectum and prostate: results of a
multi-institutional phase II trial. Radiother Oncol 106(2):215–219.
doi:10.1016/j.radonc.2012.11.009
53. Melchert C, Gez E, Bohlen G et al (2013) Interstitial biodegrad-
able balloon for reduced rectal dose during prostate radiotherapy:
results of a virtual planning investigation based on the pre- and
post-implant imaging data of an international multicenter study.
Radiother Oncol 106(2):210–214. doi:10.1016/j.radonc.2013.01.
007
54. Song DY, Herfarth KK, Uhl M et al (2013) A multi-institutional
clinical trial of rectal dose reduction via injected polyethylene-
glycol hydrogel during intensity modulated radiation therapy for
prostate cancer: analysis of dosimetric outcomes. Int J Radiat
Oncol Biol Phys 87:81–87. doi:10.1016/j.ijrobp.2012.12.019
55. Strom TJ, Wilder RB, Fernandez DC et al (2014) A dosimetric
study of polyethylene glycol hydrogel in 200 prostate cancer pa-
tients treated with high-dose rate brachytherapy±intensity modu-
lated radiation therapy. Radiother Oncol 111:126–131. doi:10.
1016/j.radonc.2014.02.011
56. Vanneste BG, Pijls-Johannesma M, Van De Voorde L, van Lin
EN, van de Beek K, van Loon J, Ramaekers BL, Lambin P
(2015) Spacers in radiotherapy treatment of prostate cancer: is
reduction of toxicity cost-effective? Radiother Oncol 114(2):
276–281. doi:10.1016/j.radonc.2015.01.005
57. Denton A, Andreyev J, Forbes A, Maher EJ (2002) Non-surgical
interventions for late radiation proctitis in patients who have re-
ceived radical radiotherapy to the pelvis. Cochrane Database Syst
Rev 1, CD003455. doi:10.1002/14651858.CD003455
58. Hanson B, MacDonald R, Shaukat A (2012) Endoscopic and
medical therapy for chronic radiation proctopathy: a systematic
review. Dis Colon Rectum 55(10):1081–1095. doi:10.1097/dcr.
0b013e3182587aef
59. Mendenhall WM, McKibben BT, Hoppe BS, Nichols RC,
Henderson RH, Mendenhall NP (2014) Management of radiation
proctitis. Am J Clin Oncol 37(5):517–523. doi:10.1097/coc.
0b013e318271b1aa
60. Andreyev HJN, Davidson SE, Gillespie C et al (2012) Practice
guidance on the management of acute and chronic gastrointestinal
problems arising as a result of treatment for cancer. Gut 61(2):
179–192. doi:10.1136/gutjnl-2011-300563
61. Kochhar R, Patel F, Dhar A, Sharma SC, Ayyagari S, Aggarwal R,
Goenka MK, Gupta BD, Mehta SK (1991) Radiation-induced
proctosigmoiditis. Prospective, randomized, double-blind con-
trolled trial of oral sulfasalazine plus rectal steroids versus rectal
sucralfate. Dig Dis Sci 36(1):103–107. doi:10.1007/bf01300096
62. Kochhar R, Sriram PV, Sharma SC, Goel RC, Patel F (1999)
Natural history of late radiation proctosigmoiditis treated with
topical sucralfate suspension. Dig Dis Sci 44(5):973–978. doi:
10.1023/A:1026612731210
63. Cavcic J, Turcic J, Martinac P et al (2000) Metronidazole in the
treatment of chronic radiation proctitis: clinical trial. Croat Med J
41:314–318
64. Ehrenpreis E, Jani A, Levitsky J et al (2005) A prospective, ran-
domized, double-blind, placebo-controlled trial of retinol palmi-
tate (vitamin A) for symptomatic chronic radiation proctopathy.
Dis Colon Rectum 48:1–8. doi:10.1007/s10350-004-0821-7
65. Clarke RE, Tenorio LM, Hussey JR et al (2008) Hyperbaric oxy-
gen treatment of chronic refractory radiation proctitis: a random-
ized and controlled double-blind crossover trial with long-term
follow-up. Int J Radiat Oncol Biol Phys 72:134–143. doi:10.
1016/j.ijrobp.2007.12.048
66. Szabo S, Vattay P, Scarbrough E et al (1991) Role of vascular
factors, including angiogenesis, in the mechanisms of action of
sucralfate. Am J Med 91:S158–S160. doi:10.1016/0002-
9343(91)90469-e
67. Hanauer SB (1990) Inflammatory bowel disease revisited: newer
drugs. Scand J Gastroenterol Suppl 25(s175):97–106. doi:10.
3109/00365529009093133
68. Goodman LS, Gilman A (1996) The pharmacological basis of
therapeutics, 9th edn. McGraw-Hill, New York, pp 995–998
69. Shadad AK, Sullivan FJ, Martin JD, Egan LJ (2013)
Gastrointestinal radiation injury: prevention and treatment.
World J Gastroenterol 19(2):199–208. doi:10.3748/wjg.v19.i2.
199
70. Kennedy M, Bruninga K, Mutlu EA, Losurdo J, Choudhary S,
Keshavarzian A (2001) Successful and sustained treatment of
chronic radiation proctitis with antioxidant vitamins E and C.
Am J Gastroenterol 96:1080–1084. doi:10.1111/j.1572-0241.
2001.03742.x
71. Feldmeier JJ, Hampson NB (2002) A systematic review of the
literature reporting the application of hyperbaric oxygen preven-
tion and treatment of delayed radiation injuries: an evidence based
approach. Undersea Hyperb Med 29:4–30
72. Marx RE (1983) A new concept in the treatment of
osteoradionecrosis. J Oral Maxillofac Surg 41:351–357. doi:10.
1016/s0278-2391(83)80005-6
73. Marx RE, Ehler WJ, Tayapongsak P et al (1990) Relationship of
oxygen dose to angiogenesis induction in irradiated tissue. Am J
Surg 160:519–524
74. Bennett MH, Feldmeier J, Hampson N, Smee R,Milross C (2012)
Hyperbaric oxygen therapy for late radiation tissue injury.
Cochrane Database Syst Rev 5, CD005005. doi:10.1002/
14651858.CD005005.pub3
75. Kishan AU, Kupelian PA (2015) Late rectal toxicity after low-
dose-rate brachytherapy: incidence, predictors, and management
of side effects. Brachytherapy 14(2):148–159. doi:10.1016/j.
brachy.2014.11.005
76. Phan J, SwansonDA, Levy LB, Kudchadker RJ, Bruno TL, Frank
SJ (2009) Late rectal complications after prostate brachytherapy
Int J Colorectal Dis (2015) 30:1293–1303 1301
for localized prostate cancer: incidence and management. Cancer
115(9):1827–1839. doi:10.1002/cncr.24223
77. Farin G, Grund KE (1994) Technology of argon plasma coagula-
tion with particular regard to endoscopic applications. Endosc
Surg Allied Technol 2:71–77
78. Tjandra JJ, Sengupta S (2001) Argon plasma coagulation is an
effective treatment for refractory hemorrhagic radiation proctitis.
Dis Colon Rectum 44(12):1759–1765. doi:10.1007/bf02234451
79. SwanMP,Moore GT, SievertWet al (2010) Efficacy and safety of
single session argon plasma coagulation in the management of
chronic radiation proctitis. Gastrointest Endosc 72:150–154. doi:
10.1016/j.gie.2010.01.065
80. Villavicencio RT, Rex DK, Rahmani E (2002) Efficacy and com-
plications of argon plasma coagulation for hematochezia related to
radiation proctopathy. Gastrointest Endosc 55(1):70–74. doi:10.
1067/mge.2002.119877
81. Karamanolis G, Triantafyllou K, Tsiamoulos Z, Polymeros D,
Kalli T, Misailidis N, Ladas SD (2009) Argon plasma coagulation
has a long-lasting therapeutic effect in patients with chronic radi-
ation proctitis. Endoscopy 41(6):529–531. doi:10.1055/s-0029-
1214726
82. Soussan BE, Mathieu N, Roque I, Antonietti M (2003) Bowel
explosion with colonic perforation during argon plasma coagula-
tion for hemorrhagic radiation-induced proctitis. Gastrointest
Endosc 57(3):412–413. doi:10.1067/mge.2003.131
83. Taieb S, Rolachon A, Cenni JC et al (2001) Effective use of argon
plasma coagulation in the treatment of severe radiation proctitis.
Dis Colon Rectum 44(12):1766–1771. doi:10.1007/bf02234452
84. Canard JM, Védrenne B, Bors G et al (2003) Long term results of
treatment of hemorrhagic radiation proctitis by argon plasma co-
agulation. Gastroenterol Clin Biol 27(5):455–459
85. Dees J, Maarten AC, Meijssen MA, Kuipers EJ (2006) Argon
plasma coagulation for radiation proctitis. Scand J Gastroenterol
Suppl 41(s243):175–178. doi:10.1080/00365520600664300
86. Fenwick JD, Khoo VS, Nahum AE, Sanchez-Nieto B, Dearnaley
DP (2001) Correlations between dose-surface histograms and the
incidence of long-term rectal bleeding following conformal or
conventional radiotherapy treatment of prostate cancer. Int J
Radiat Oncol Biol Phys 49(2):473–480
87. Rotondano G, Bianco MA, Marmo R et al (2003) Long-term
outcome of argon plasma coagulation therapy for bleeding caused
by chronic radiation proctopathy. Dig Liver Dis 35(11):806–810.
doi:10.1016/s1590-8658(03)00454-7
88. Tam W, Moore J, Schoeman M (2000) Treatment of radiation
proctitis with argon plasma coagulation. Endoscopy 32(9):667–
672. doi:10.1055/s-2000-9020
89. Zinicola R, Rutter MD, Falasco G, Brooker JC, Cennamo V,
Contini S, Saunders BP (2003) Haemorrhagic radiation proctitis:
endoscopic severity may be useful to guide therapy. Int J Color
Dis 18(5):439–444. doi:10.1007/s00384-003-0487-y
90. Venkatesh KS, Ramanujam P (2002) Endoscopic therapy for ra-
diation proctitis-induced hemorrhage in patients with prostatic car-
cinoma using argon plasma coagulator application. Surg Endosc
16(4):707–710. doi:10.1007/s00464-001-8164-0
91. Ravizza D, Giancarla F, Trovato C, Crosta C (2003) Frequency
and outcomes of rectal ulcers during argon plasma coagulation for
chronic radiation-induced proctopathy. Gastrointest Endosc 57(4):
519–525. doi:10.1067/mge.2003.144
92. Andreyev HJ (2007) Argon plasma coagulation in chronic radia-
tion proctitis: Postgate et al. Endoscopy 39(8):751–752. doi:10.
1055/s-2007-966772
93. Andreyev HJ (2007) Gastrointestinal symptoms after pelvic radio-
therapy: a new understanding to improve management of symp-
tomatic patients. Lancet Oncol 8(11):1007–1017. doi:10.1016/
s1470-2045(07)70341-8
94. Sebastian S, O’Connor H, O’Morain C et al (2004) Argon plasma
coagulation as first-line treatment for chronic radiation
proctopathy. J Gastroenterol Hepatol 19(10):1169–1173. doi:10.
1111/j.1440-1746.2004.03448.x
95. Haas EM, Bailey HR, Farragher I (2007) Application of 10 per-
cent formalin for the treatment of radiation-induced hemorrhagic
proctitis. Dis Colon Rectum 50(2):213–217. doi:10.1007/s10350-
006-0707-y
96. Parikh S, Hughes C, Salvati EP, Eisenstat T, Oliver G, Chinn B,
Notaro J (2003) Treatment of hemorrhagic radiation proctitis with
4 percent formalin. Dis Colon Rectum 46(5):596–600. doi:10.
1007/s10350-004-6614-1
97. Henson C (2010) Chronic radiation proctitis: issues surrounding
delayed bowel dysfunction post-pelvic radiotherapy and an update
on medical treatment. Ther Adv Gastroenterol 3(6):359–365. doi:
10.1177/1756283x10371558
98. Seow-Chen F, Goh H, Eu K, Ho Y, Tay S (1993) A simple and
effective treatment for hemorrhagic radiation proctopathy using
formalin. Dis Colon Rectum 36(2):135–138. doi:10.1007/
bf02051168
99. Biswal B, Lal P, Rath G, Shukla N, Mohanti B, Deo S (1995)
Intrarectal formalin application, an effective treatment for grade
III haemorrhagic radiation proctitis. Radiother Oncol 35(3):212–
215. doi:10.1016/0167-8140(95)01565-x
100. Saclarides T, King D, Franklin J, Doolas A (1996) Formalin in-
stallation for refractory radiation-induced hemorrhagic proctitis.
Dis Colon Rectum 39(2):196–199. doi:10.1007/bf02068075
101. Roche B, Chauterns R, Marti M (1996) Application of formalde-
hyde for treatment of hemorrhagic radiation-induced proctitis.
World J Surg 20(8):1092–1095. doi:10.1007/s002689900166
102. Counter S, Froese D, Hart M (1999) Prospective evaluation of
formalin therapy for radiation proctitis. Am J Surg 177(5):396–
398. doi:10.1016/s0002-9610(99)00072-0
103. Luna-Pérez P, Rodríguez-Ramírez SE (2002) Formalin instillation
for refractory radiation-induced hemorrhagic proctitis. J Surg
Oncol 80(1):41–44. doi:10.1002/jso.10095
104. de Parades V, Etienney I, Bauer P, Bourguignon J, Meary N, Mory
B, Sultan S, Taouk M, Thomas C, Atienza P (2005) Formalin
application in the treatment of chronic radiation-induced hemor-
rhagic proctitis—an effective but not risk-free procedure: a pro-
spective study of 33 patients. Dis Colon Rectum 48(8):1535–
1541. doi:10.1007/s10350-005-0030-z
105. Raman RR (2007) Two percent formalin retention enemas for
hemorrhagic radiation proctitis: a preliminary report. Dis Colon
Rectum 50(7):1032–1039. doi:10.1007/s10350-007-0241-6
106. Sharma B, Kumar R, Singh KK, Chauhan V (2010) Intrarectal
application of formalin for chronic radiation proctitis: a simple,
cheap and effective treatment. Trop Gastroenterol 31(1):37–40
107. Nelamangala Ramakrishnaiah VP, Javali TD, Dharanipragada K,
Reddy KS, Krishnamachari S (2012) Formalin dab, the effective
way of treating haemorrhagic radiation proctitis: a randomized
trial from a tertiary care hospital in South India. Color Dis 14(7):
876–882. doi:10.1111/j.1463-1318.2012.03008.x
108. Sánchez HA, del Vicente Sánchez MP, Arteta Jiménez M (2012)
Formalin for haemorrhagic radiation-induced proctitis. Int J Color
Dis 27(5):683–685. doi:10.1007/s00384-011-1268-7
109. Pironi D, Panarese A, Vendettuoli M, Pontone S, Candioli S,
Manigrasso A, De Cristofaro F, Filippini A (2013) Chronic
radiation-induced proctitis: the 4 % formalin application as non-
surgical treatment. Int J Color Dis 28(2):261–266. doi:10.1007/
s00384-012-1571-y
110. PikarskyAJ, Belin B, Efron J,Weiss EG, Nogueras JJ,Wexner SD
(2000) Complications following formalin installation in the treat-
ment of radiation-induced proctitis. Int J Color Dis 15(2):96–99.
doi:10.1007/s003840050240
1302 Int J Colorectal Dis (2015) 30:1293–1303
111. Yeoh E, TamW, SchoemanM, Moore J, Thomas M, Botten R, Di
Matteo A (2013) Argon plasma coagulation therapy versus topical
formalin for intractable rectal bleeding and anorectal dysfunction
after radiation therapy for prostate carcinoma. Int J Radiat Oncol
Biol Phys 87(5):954–959. doi:10.1016/j.ijrobp.2013.08.034
112. Alfadhli AA, Alazmi WM, Ponich T, Howard JM, Prokopiw I,
Alaqeel A, Gregor JC (2008) Efficacy of argon plasma coagula-
tion compared with topical formalin application for chronic radia-
tion proctopathy. Can J Gastroenterol 22(2):129–132
113. De Palma GD (2009) Confocal laser endomicroscopy in the
Bin vivo^ histological diagnosis of the gastrointestinal tract.
World J Gastroenterol 15(46):5770–5775. doi:10.3748/wjg.15.
5770
114. Taylor JG, Disario JA, Bjorkman DJ (2000) KTP laser therapy for
bleeding from chronic radiation proctopathy. Gastrointest Endosc
52(4):353–357. doi:10.1067/mge.2000.107726
115. Do NL, Nagle D, Poylin VY (2011) Radiation proctitis: current
strategies in management. Gastroenterol Res Pract 2011:1–9. doi:
10.1155/2011/917941
116. Lucarotti M, Mountford R, Bartolo D (1991) Surgical manage-
ment of intestinal radiation injury. Dis Colon Rectum 34(10):
865–869. doi:10.1007/bf02049698
117. YegappanM, Ho YH, NyamD, Leong A, Eu KW, Seow C (1998)
The surgical management of colorectal complications from irradi-
ation for carcinoma of the cervix. Ann Acad Med Singap 27(5):
627–630
118. Fischer L, Kimose HH, Spjeldnaes N, Wara P (1990) Late progress
of radiation-induced proctitis. Acta Chir Scand 156(11–12):801–805
119. Lane BR, Stein DE, Remzi FH, Strong SA, Fazio VW,
Angermeier KW (2006) Management of radiotherapy induced
rectourethral fistula. J Urol 175(4):1382–1387
120. Turina M, Mulhall AM, Mahid SS, Yashar C, Galandiuk S (2008)
Frequency and surgical management of chronic complications re-
lated to pelvic radiation. Arch Surg 143(1):46–52. doi:10.1001/
archsurg.2007.7
Int J Colorectal Dis (2015) 30:1293–1303 1303
